# BPC-157 legal status, FDA 503A category, and compounding access | BPC-157

> BPC-157 legal status: FDA placed it in 503A Category 2 (effective 2023-09-29) and it is on the July 2026 PCAC agenda as a substance under evaluation. Current FDA facts, cited; no future decision asserted.

Access is under active FDA review and may expand in 2026 — but as of now BPC-157 sits in 503A Category 2. This page states the current facts, cites FDA, and asserts no future decision as certain.

## The Forward-Leaning Fact: BPC-157 Is on the July 2026 PCAC Agenda

The BPC-157 legal status is in motion, and the forward-leaning fact is concrete: BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — the same agenda that also lists KPV, TB-500, and MOTs-C [18]. In that precise sense, access to compounded BPC-157 is under active FDA review and may expand in 2026.

That momentum deserves to be stated plainly, and so does its boundary. A PCAC agenda item is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in BPC-157's current status [18]. The committee is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking, informed by — but not bound by — PCAC [17]. The accurate reading of mid-2026 is therefore narrow and real at once: a named substance, on the agenda, under evaluation, with no outcome assumed, stated, or dated [18].

## The Current FDA Fact, Stated Present-Tense

As of now, BPC-157 — FDA evaluated the list entries "BPC-157 (free base)" and "BPC-157 acetate" — is a research peptide that FDA placed in 503A "Category 2," the category of bulk substances FDA has identified as potentially presenting significant safety risks [16]. The placement is effective with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A [16]. FDA's stated rationale includes concerns about potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [16].

Two consequences follow directly. First, as a Category 2 substance, BPC-157 is not covered by FDA's enforcement-discretion policy for 503A compounding — the policy that applies to Category 1 substances does not extend to it [16][17]. Second, BPC-157 is not an FDA-approved drug; approval of a finished drug is a separate question from whether a bulk substance may be used in compounding, and BPC-157 holds neither status [17].

## How the 503A and 503B Framework Works

Under the U.S. Federal Food, Drug, and Cosmetic Act, two sections govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [17].

A compounder may use a bulk drug substance only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet on a list are evaluated by FDA through a public nomination process with PCAC input [17]. FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks; not covered). On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 2 are not afforded that discretion even if nominations are updated [17][19]. Against that backdrop, BPC-157 remains in Category 2 — the last FDA action confirmable from FDA.gov [16].

## What This Means for Compounded Access

How does legally compounded peptide access work in general? A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [17]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility [17].

Telehealth, where used, is simply the front-end channel for that prescriber-evaluation step; it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical relationship and a valid prescription [17]. The decisive caveat sits at the ingredient. A compounded preparation may lawfully be made only when its active ingredient is eligible under the 503A/503B framework, and a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [17]. For BPC-157, that ingredient-eligibility constraint is the operative one today [16]. This page names no specific pharmacy, clinic, telehealth provider, or vendor, gives no dosing, and describes no way to obtain a restricted substance outside the lawful framework — it is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.

## Is BPC-157 legal?

BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — bulk substances identified as potentially presenting significant safety risks — effective with its September 29, 2023 update [16]. It is also prohibited in sport at all times by the World Anti-Doping Agency under the non-approved-substances category. Legality depends on jurisdiction and use-context; this page describes the U.S. compounding-regulatory landscape, not a blanket legal verdict.

## Can you get BPC-157 from a compounding pharmacy?

Not through routine 503A compounding while its current status stands. In its September 29, 2023 update, FDA placed BPC-157 in Category 2, which sits outside FDA's enforcement-discretion policy for 503A compounding [16]. A Category 2 substance is not eligible for routine 503A compounding, so a licensed prescriber's evaluation alone does not make the ingredient eligible [17]. BPC-157 is, however, scheduled for PCAC discussion in July 2026 as a candidate for the bulks list — an evaluation, not a decision [18].

## What is the FDA 503A status of BPC-157?

BPC-157 was identified by FDA as a bulk drug substance placed in 503A Category 2 — potentially presenting significant safety risks — effective with its September 29, 2023 nominated-substances update, and it is therefore not within FDA's enforcement-discretion policy for 503A compounding [16]. The entries FDA evaluated are "BPC-157 (free base)" and "BPC-157 acetate" [16]. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance being considered for the 503A Bulks List, which is a scheduled discussion and not a listing decision or a reclassification [18].

---

A color-blocked reading board for the BPC-157 record — each tissue, the VEGFR2 mechanism, the three human pilots, and the FDA 503A status set in its own plum-and-pop panel and cited to source, with no clinic behind the board and nothing here dispensed or sold.